Background: The authors evaluated the influence of temperature on the pharm
acokinetics and pharmacodynamics of vecuronium because mild core hypothermi
a doubles its duration of action.
Methods: Anesthesia was induced with alfentanil and propofol and maintained
with nitrous oxide and isoflurane in 12 healthy volunteers. Train-of-four
stimuli were applied to the ulnar nerve, and the mechanical response of the
adductor pollicis was measured. Volunteers were actively cooled or warmed
until their distal esophageal temperatures were in one of four ranges: < 35
.0 degrees C, 35.0-35.9 degrees C, 36.0-36.9 degrees C, and greater than or
equal to 37.0 degrees C. With temperature stabilized, vecuronium was infus
ed at 5 mu g . kg(-1) . min(-1) until the first response of each train-of-f
our had decreased by 70%. Arterial blood (for vecuronium analysis) was samp
led at intervals until the first response recovered to at least 90% of its
prevecuronium level. Vecuronium, 20 mu g . kg(-1) . min(-1), was then infus
ed for 10 min, and arterial blood was sampled at intervals for up to 7 h. p
opulation-based nonlinear mixed-effects modeling was used to examine the ef
fect of physical characteristics and core temperature on vecuronium pharmac
okinetics and pharmacodynamics.
Results: Decreasing core temperature over 38.0-34.0 degrees C decreases the
plasma clearance of vecuronium (11.3% per degrees C), decreases the rate c
onstant for drug equilibration between plasma and effect site (0.023 min(-1
) per degrees C), and increases the slope of the concentration-response rel
ationship (0.43 per degrees C).
Conclusions: Our results show that reduced clearance and rate of effect sit
e equilibration explain the increased duration of action of vecuronium with
reducing core temperature. Tissue sensitivity to vecuronium is not influen
ced by core temperature.